Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Cumulative Benefits of Extended-Release Memantine (28 mg, Once Daily) Across Clinical Domains in Patients With Moderate to Severe Alzheimer's Disease: An Area Under the Curve Analysis
The American Journal of Geriatric Psychiatry · Vol. 22 Published January 1, 2014
More on these topics
Browse all publications →-
2019 · Neurology
The Effects of Memantine Added to Cholinesterase Inhibitors on NPI Behavioral Domains: Pooled Post Hoc Analysis of 3 Randomized Controlled Trials in Patients With Moderate to Severe AD (S9. 008)
-
2019 · Neurology
SIB Maintenance of Response With Memantine Added to Cholinesterase Inhibitors: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD (P4. 1-008)
-
2019 · Neurology
Efficacy of Memantine Added to Cholinesterase Inhibitors on SIB Higher-Order Cognitive Domains: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD (P4. 1-007)
-
2018 · Alzheimer Disease & Associated Disorders
Memantine ER maintains patient response in moderate to severe Alzheimer's disease: post hoc analyses from a randomized, controlled, clinical trial of patients treated with cholinesterase inhibitors